ストックスクリーナーアプリを入手
2.21
3.07%
-0.07
アフターアワーズ：
2.21
前日終値:
$2.28
開ける：
$2.13
24時間の取引高:
5.24M
Relative Volume:
2.08
時価総額：
$65.78M
収益：
-
当期純損益:
$-13.08M
株価収益率:
-5.0045
EPS:
-0.4416
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+88.89%
1か月 パフォーマンス:
+25.57%
6か月 パフォーマンス:
-55.17%
1年 パフォーマンス:
-41.07%
1日の値動き範囲:
$2.04
$2.28
1週間の範囲:
$1.13
$3.10
52週間の値動き範囲:
$1.12
$8.40
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
TELO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
2.21 | 34.82M | 0 | -13.08M | 0 | -0.4416 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-21 | 開始されました | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc (TELO) 最新ニュース
Pre-market Movers: PMN, GCTK, TELO, SRPT... - RTTNews
Is Telomir Pharmaceuticals Inc. a good long term investmentSuperior investment outcomes - Autocar Professional
What analysts say about Telomir Pharmaceuticals Inc. stockTremendous growth opportunities - Autocar Professional
Telomir Pharmaceuticals Inc. Stock Analysis and ForecastExceptional gains - jammulinksnews.com
What drives Telomir Pharmaceuticals Inc. stock priceDynamic investment opportunities - Autocar Professional
Why Is Telomir Pharmaceuticals Stock (TELO) Up 150% Today? - MSN
Healthcare Stocks Move in Pre-Market Session: Telomir Pharmaceuticals, Mesoblast, and More - AInvest
Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin - Lohud
Telomir Pharmaceuticals Stock Price, Quotes and Forecasts - Benzinga
Telomir skyrockets on preclinical data backing epigenetic potential of lead asset - FirstWord Pharma
Dow Falls Over 200 Points; 3M Earnings Top Views - Benzinga
Telomir Pharma Skyrockets Nearly 139% After-Hours As Cancer Drug Shows Breakthrough Results, Beats Chemo In Human Cell Tests - NewsBreak: Local News & Alerts
Telomir Pharmaceuticals Skyrockets 150% on Breakthrough Preclinical Cancer Results - MSN
Telomir Pharmaceuticals: A Disruptive Force in Prostate Cancer Therapy with Epigenetic Innovation - AInvest
Telomir Pharmaceuticals stock soars after promising cancer treatment data - Investing.com
Telomir Pharma Jumps In After-Hours Trading After Drug Reverses Damage In Progeria Cells; Retail Eyes Bigger Gains - Stocktwits
Telomir Pharmaceuticals stock soars after promising cancer treatment data By Investing.com - Investing.com UK
Cancer Breakthrough Sends Telomir Pharma Stock Exploding 157% - Wall Street Pit
Telomir-1 shows stronger epigenetic effects than standard drugs in cancer study - Investing.com Australia
Telomir-1 shows stronger epigenetic effects than standard drugs in cancer study By Investing.com - Investing.com South Africa
Revolutionary Cancer Treatment Shows 50% Tumor Reduction, Beats Standard Chemotherapy in Clinical Tests - Stock Titan
TELO’s Stock Tango: The Dance of Gains and Losses in 2025 - investchronicle.com
Published on: 2025-07-18 16:06:06 - jammulinksnews.com
Telomir Pharmaceuticals Stock Soars 123.97% on Promising Cancer Drug Data - AInvest
Telomir Pharma Jumps In After-Hours Trading After Drug Reverses Damage In Progeria Cells Retail Eyes Bigger Gains - Menafn.com
Telomir says data show Telomir-1 reversed epigenetic silencing - TipRanks
What makes Telomir Pharmaceuticals Inc. stock price move sharplySmart Money Trade Setups - Newser
How Telomir Pharmaceuticals Inc. stock performs during market volatilityProfit Focused Trade Alerts - Newser
Why Telomir Pharmaceuticals Inc. stock attracts strong analyst attentionStable Stocks With High Yield - Newser
Telomir Pharmaceuticals (NASDAQ:TELO) Trading Down 18.3% – Should You Sell? - Defense World
Telomir Pharmaceuticals, Inc.(NasdaqCM: TELO) dropped from Russell 3000 Value Index - MarketScreener
TELO Rises on Promising Telomir-1 Preclinical Results - MSN
Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeriaan Ultra-Rare Genetic Disorder that Causes Rapid Aging - Knoxville News Sentinel
# Telomir-1 shows anti-aging effects in progeria cell study By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals reports positive results for progeria treatment By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals Inc (TELO) 財務データ
収益
当期純利益
現金流量
EPS
0.87%
0.17%
大文字化:
|
ボリューム (24 時間):